WGS(GeneDx Holdings Corp.) 的财务报表:医疗保健,诊断与研究。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $212.19M | $234.69M | $202.57M | $305.45M | $427.54M |
| 毛利润 | −$16.60M | −$26.75M | $90.01M | $194.40M | $298.17M |
| 营业利润 | −$446.15M | −$667.65M | −$180.60M | −$23.21M | −$13.08M |
| 净利润 | −$245.39M | −$548.98M | −$175.77M | −$52.29M | −$21.02M |
| 经营现金流 | −$190.43M | −$319.15M | −$180.15M | −$28.50M | $33.28M |
| 自由现金流 | −$199.83M | −$326.31M | −$185.40M | −$33.99M | $14.26M |
| 摊薄每股收益 | $-74.91 | $-53.63 | $-7.23 | $-1.94 | $-0.73 |